Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1467335 in Healthy Japanese and Caucasian Males
NCT03159455Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) and diabetic retinopathy (DR) comparing BI 1467335 with Placebo (2 arms). Primary endpoint: Percentage of Subjects With Drug-related Adverse Events up to 48 days. Started Jun 2017; status: completed.
02
Drugs
PXS-4728A
03
Conditions
Nonalcoholic steatohepatitis (NASH)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT03159455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159455.